JAN - JanOne announces clinical batch production of JAN101 for mid-stage study

JanOne ([[JAN]] -7.2%) has started production of JAN101 for its anticipated Phase 2b trials in Peripheral Artery Disease ((PAD)) and as a potential treatment for COVID-19 vascular complications.The initial production batch will be 250k sustained release tablets and matching placebos. The Phase 2b trial is expected to begin in early 2021.JAN101 is a sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow.

For further details see:

JanOne announces clinical batch production of JAN101 for mid-stage study